In IDH-mutant astrocytomas, the development of these MMR gene mutations was significantly correlated with TMZ therapy between the primary tumor and recurrent specimen, although it remains unclear why MMR mutation only occurred in a subset of treated cases. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).